期刊
FRONTIERS IN ONCOLOGY
卷 5, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2015.00193
关键词
human tumor xenografts; drug sensitivity; expression profiling; copy number variation; preclinical pharmacology; bioinformatics; biomarkers; drug efficacy
类别
资金
- USPHS from the National Cancer Institute (USA) [NO1-CM42216]
Over the past 35 years, cure rates for pediatric cancers have increased dramatically. However, it is clear that further dose intensification using cytotoxic agents or radiation therapy is not possible without enhancing morbidity and long-term effects. Consequently, novel, less genotoxic, agents are being sought to complement existing treatments. Here, we discuss preclinical human tumor xenograft models of pediatric cancers that may be used practically to identify novel agents for soft tissue and bone sarcomas, and omics approaches to identifying biomarkers that may identify sensitive and resistant tumors to these agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据